Back to top

Image: Bigstock

Invesco Closes OppenheimerFunds Buyout, Assets Rise to $1.2T

Read MoreHide Full Article

Invesco IVZ has completed the acquisition of MassMutual’s asset management unit, OppenheimerFunds, Inc. The deal, announced in October 2018, significantly boosted the company’s assets under management (AUM), bringing total AUM to around $1.2 trillion.

Following the completion, Invesco has become one of the leading global investment managers. This will likely further strengthen the company’s “ability to help meet client needs through its comprehensive range of high-conviction active, passive and alternative capabilities.”

Martin L. Flanagan, president and CEO of Invesco, said, “We will leverage the combined firm's highly talented team of professionals, expanded set of capabilities and deep global presence to continue providing tailored solutions that help our clients around the world achieve their investment objectives.”

Deal Benefits & Other Details

The deal is expected to be accretive to Invesco’s adjusted earnings immediately. It is projected to be roughly 24 cents per share accretive in 2019, and 58 cents per share accretive in 2020. Also, Invesco and MassMutual will likely continue to explore future strategic tie ups.

Per the terms, the agreement consideration comprises roughly 81.9 million Invesco shares (including approximately 6 million shares issued as part of the conversion of unvested restricted stock awards held by OppenheimerFunds employee shareholders into Invesco restricted stock awards) and nearly $4 billion worth of 5.9% fixed rate perpetual, non-cumulative preferred shares with a 21-year non-call period.

As a result of such a deal arrangement, now MassMutual is a significant stakeholder in Invesco, with nearly 15.7% holdings in the common stock.

Further, Invesco and MassMutual entered into a shareholder agreement, which gave MassMutual customary minority shareholder rights, including representation on Invesco's board of directors. MassMutual has nominated William F. Glavin, Jr., the retired CEO of MassMutual, to Invesco’s board.


Invesco’s acquisition of OppenheimerFunds will go a long way in supporting the company’s financials and will also expand its global reach. The company’s shares have rallied 22% so far this year, outperforming the industry’s rise of 12.4%.

Currently, Invesco carries a Zacks Rank #3 (Hold).

Amid a tough operation environment, the asset management industry is expected to see further consolidation in order to meet client needs with a wide range of capabilities. In March, Oaktree Capital Group, LLC OAK announced a deal, wherein Brookfield Asset Management Inc will acquire nearly 62% stake in the former. The combined company is expected to have nearly $475 billion in AUM and $2.5 billion of annual fee-related revenues, post completion. (Read more: Brookfield Agrees to Buy 62% Stake in Oaktree Capital)

Stocks Worth a Look

BlackRock BLK has been witnessing upward estimate revisions over the past 60 days. Moreover, this Zacks Rank #1 (Strong Buy) stock has rallied 10.9% so far this year. You can seethe complete list of today’s Zacks #1 Rank stocks here.

Cohen & Steers Inc (CNS - Free Report) has been witnessing upward estimate revisions over the past 60 days. Also, the stock has surged 49.4% so far this year. It currently sports a Zacks Rank #1.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Cohen & Steers Inc (CNS) - free report >>